Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA repair enzymes are a broad family of enzymes responsible for the recognition and correction of a variety of DNA lesions to maintain genome integrity[2][4][3]. Major subclasses include glycosylases, polymerases, endonucleases, photolyases, and dioxygenases, each typically specialized for a particular repair pathway (e.g., base excision repair, nucleotide excision repair, mismatch repair, direct reversal, or recombination repair)[1][2][3][5]. Dysfunction in DNA repair enzymes is associated with increased mutation rates and susceptibility to diseases such as cancer and neurodegenerative disorders[3]. Therapies targeting these enzymes, for instance PARP inhibitors, exploit tumor-specific DNA repair deficiencies to induce synthetic lethality, making DNA repair enzymes a significant focus in oncology drug development[4].
Inhibition of specific DNA repair pathways (e.g., PARP inhibition blocks single-strand break repair, leading to synthetic lethality in tumor cells with homologous recombination defects); Modulation or activation of repair enzymes to restore DNA integrity
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA repair enzyme.